(Q39460944)

English

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

scientific article published on 9 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Malin Wickström

object named as

Malin Wickström

6

0 references

7

object named as

Rolf Larsson

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

3

object named as

Peter Nygren

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

4

object named as

Joachim Gullbo

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Caroline Haglund

1

object named as

Caroline Haglund

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

2

object named as

Anna Aleskog

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

author name string

Martin Höglund

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Elin Lindhagen

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

9 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

697-707

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Human primary renal cells as a model for toxicity assessment of chemo-therapeutic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Cell-based assays for profiling activity and safety properties of cancer drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

The fluorometric microculture cytotoxicity assay

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Anticancer drug-induced kidney disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

FLT3 inhibition as a targeted therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Gefitinib induces myeloid differentiation of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Proteomic and genetic approaches identify Syk as an AML target

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1746-1

21 January 2018

Identifiers

10.1007/S00280-011-1746-1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39460944&oldid=2202901972"